[{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase II","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase II","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase II","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Collegium Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ironshore Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ BioDelivery Sciences","highestDevelopmentStatusID":"11","companyTruncated":"BioDelivery Sciences \/ BioDelivery Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ PRA Health Sciences","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ PRA Health Sciences"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Collegium Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Endo Pharm"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0.38,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"EN3409","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioDelivery Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioDelivery Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ajay Wasan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Ajay Wasan","highestDevelopmentStatusID":"11","companyTruncated":"Collegium Pharmaceutical \/ Ajay Wasan"}]
Find Clinical Drug Pipeline Developments & Deals by Collegium Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
